Cas9 Stable Cell Line - Hepa 1-6

The Hepa 1-6 cell line, derived from mouse hepatocellular carcinoma, is an important model for liver biology, toxicology, and metabolic disease research. These cells retain hepatocyte-like characteristics, including glycogen storage and albumin production, making them ideal for studying liver-specific functions and pathology. The Cas9 Stable Cell Line - Hepa 1-6 was constructed by stably integrating the CRISPR-associated protein 9 (Cas9) endonuclease into the Hepa 1-6 genome. This modification creates a versatile platform for efficient, targeted genome editing without transient Cas9 plasmid transfection. The cell line maintains stable Cas9 expression during passage, ensuring consistent editing efficiency and minimizing experimental error. Its mouse origin also allows for seamless integration with in vivo studies, bridging cell and in vivo research.

This Cas9 Stable Cell Line - Hepa 1-6 accelerates various applications in biomedical research. In functional genomics, the system enables high-throughput gene knockout screening to identify genes regulating hepatocellular carcinoma progression, drug metabolism, and viral infection mechanisms (e.g., hepatitis B/C). In drug development, researchers use this system to rapidly construct homologous disease models (e.g., lipid metabolism gene mutations to mimic non-alcoholic fatty liver disease/non-alcoholic steatohepatitis), thereby validating therapeutic targets and screening compounds. In gene therapy development, the system helps to accurately evaluate CRISPR-based monogenic liver disease correction strategies. Furthermore, its application in toxicity studies can elucidate the mechanisms of drug-induced liver injury by targeting genes that disrupt cytochrome P450 enzymes.